PT-141 (Bremelanotide) History & Development: From Sunburn Drug to HSDD Treatment

What Is PT-141, and Where Did It Come From?

PT-141 is the injectable peptide that became bremelanotide, now sold as Vyleesi, the only centrally acting drug approved for female sexual desire in the United States. Its path from a university laboratory tanning experiment to a women's health prescription took roughly four decades, several unexpected detours, and a complete pivot in indication. Understanding that path explains why the drug works the way it does, why it is approved only for premenopausal women, and what the evidence actually shows.

The Tanning Peptide Origins

The story starts not in sexual medicine but in skin cancer prevention research at the University of Arizona in the early 1980s. Researchers Mac Hadley and Victor Hruby were searching for a drug that could stimulate melanin production to protect fair-skinned people from UV damage. They synthesized a series of analogues of alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring peptide that signals the skin to produce melanin through melanocortin receptors.

One of those analogues, Melanotan I, did increase skin pigmentation in early human trials. A second, more potent analogue they developed, Melanotan II (MT-II), also darkened skin. But something else happened in those early studies that nobody had planned for.

The Accidental Erection Discovery

In 1996, a researcher at the Arizona team self-administered MT-II subcutaneously and reported a prolonged, spontaneous penile erection lasting approximately eight hours, along with nausea. The observation was published in the Annals of Pharmacotherapy. That single case report redirected the entire research program. The tanning project was effectively set aside. The new question became: could melanocortin activation treat erectile dysfunction?

This finding was not a trivial accident. It pointed directly to the brain and spinal cord, not the penis, as the site of action. Melanocortin receptors, specifically the MC3R and MC4R subtypes expressed in the hypothalamus and limbic system, appeared to have a direct role in sexual response circuitry. That mechanistic clue would later become the scientific rationale for studying the compound in women.

From Melanotan II to PT-141

Palatin Technologies licensed the intellectual property and began developing a stabilized analogue. PT-141 is a synthetic cyclic heptapeptide derived from MT-II, with chemical modifications designed to improve selectivity and reduce side effects while preserving the central melanocortin activity. Palatin's early pharmacology work confirmed that PT-141 activated MC3R and MC4R in the central nervous system and produced pro-erectile and pro-sexual behavioral effects in rodent models.

The "PT" in PT-141 simply stands for Palatin Technologies. The compound was later renamed bremelanotide for regulatory and commercial purposes, but the PT-141 name persists widely in clinical literature and in patient communities.

How PT-141 Works: The Melanocortin Pathway Explained

Bremelanotide does not act on sex hormones. It does not increase estrogen, testosterone, or any gonadal steroid. It does not dilate genital blood vessels the way sildenafil does. This distinction matters clinically and is often misunderstood.

Central Nervous System Mechanism

The drug binds with high affinity to melanocortin receptors 3 and 4 (MC3R and MC4R) in the brain. MC4R in particular is densely expressed in the paraventricular nucleus of the hypothalamus, a region that integrates hormonal signals, stress, and appetitive behavior, including sexual motivation. Agonism at these receptors modulates dopaminergic and oxytocin-mediated pathways that contribute to desire and arousal.

The working model, supported by animal and early human data, is that bremelanotide increases the drive toward sexual activity at the level of the central nervous system, before peripheral arousal begins. This is sometimes described as acting on "wanting" rather than "ability." In female sexual function research, the distinction between desire (motivation to seek sex) and arousal (physiological genital response) is well established, and HSDD by definition is a disorder of desire, not arousal.

Why This Matters for Women Specifically

In women, sexual desire is particularly susceptible to central inhibition by stress, relationship factors, mood, and hormonal state. The menstrual cycle itself shifts hypothalamic activity across its phases. Research has shown that spontaneous sexual desire peaks in the late follicular phase around ovulation, when estradiol is at its monthly high and central melanocortin tone may be partly hormonally modulated. During perimenopause and postmenopause, declining estradiol appears to alter hypothalamic signaling in ways that compound low desire.

Bremelanotide's central mechanism is theoretically well-matched to the female neurobiology of desire. However, the approved indication is limited to premenopausal women because that is the population studied in the key trials.

What It Does Not Do

It does not increase genital blood flow as a primary action. It does not change hormone levels. It will not treat arousal disorder, orgasm disorder, or genital pain as primary conditions. For women whose low desire has a predominantly hormonal cause, such as surgical menopause with abrupt estrogen and testosterone loss, bremelanotide addresses only one part of the picture.

Early Clinical Development: From ED Trials to Female Sexual Dysfunction

Phase 1 and 2 Studies in Men

Palatin's first human trials tested PT-141 primarily in men with erectile dysfunction. A Phase 1 intranasal formulation study published in 2004 in the International Journal of Impotence Research showed that intranasal PT-141 produced erectile responses and increased sexual desire scores in men. A subsequent Phase 2 randomized controlled trial in men confirmed the pro-erectile effect but also documented the most significant adverse effect: transient, clinically meaningful increases in blood pressure peaking at 30 to 60 minutes post-dose.

The blood pressure signal was enough to stall the erectile dysfunction program. Palatin deprioritized the male ED indication and redirected to female sexual dysfunction, where the regulatory pathway was more open and where the mechanistic argument for central desire modulation was, arguably, a better fit.

Early Phase 2 Work in Women

Between approximately 2004 and 2008, Palatin conducted Phase 2 studies in premenopausal women with female sexual dysfunction and in postmenopausal women. A Phase 2 trial published in the Journal of Sexual Medicine in 2008 tested subcutaneous PT-141 at multiple doses in premenopausal women and found statistically significant improvements in sexual desire and arousal compared to placebo. Nausea and flushing were the most common adverse effects. Blood pressure elevations were present but smaller in magnitude than those seen in male trials, a sex difference that has not been fully mechanistically explained.

One clinically useful framework for interpreting PT-141's development that has not been explicitly articulated in competitor content: the drug's trajectory illustrates a recurring pattern in women's sexual pharmacology where male-indication failures are repurposed toward female indications because the regulatory and mechanistic barriers appear lower. This is not necessarily a problem, but it means that the female-specific evidence base is thinner than the male development program, and the drug was optimized for male ED before its female indication was defined. Women deserve to know this when they are weighing a prescription.

The Key RECONNECT Trials and FDA Approval

Trial Design

The RECONNECT program comprised two parallel randomized, double-blind, placebo-controlled Phase 3 trials enrolling premenopausal women aged 18 to 50 with a diagnosis of acquired, generalized HSDD. The primary endpoints were change from baseline in the number of satisfying sexual events (SSEs) and change in the Female Sexual Distress Scale-Desire/Arousal/Orgasm score (FSDS-DAO). Both trials are reported together in the 2019 publication in Obstetrics and Gynecology, the ACOG journal, a women's-health primary source.

What the Trials Found

Across both studies, women using bremelanotide 1.75 mg reported approximately 0.5 more satisfying sexual events per month compared to placebo, and a mean FSDS-DAO improvement of roughly 3 to 4 points more than placebo. The FDA's 2019 summary review characterized these as statistically significant but modest in absolute magnitude. About 25% of women on active drug were classified as responders using a composite definition, versus about 17% on placebo.

The trials enrolled women who were in stable relationships, not depressed, and not using hormonal contraception that might confound desire. This is a narrow slice of real-world premenopausal women with HSDD.

The Evidence Gap

Women have been historically underrepresented in sexual pharmacology trials, and RECONNECT is one of the few large, placebo-controlled trials designed specifically for a female sexual indication. That is worth acknowledging. At the same time, the effect sizes are modest, the mechanism in women is extrapolated substantially from male data and animal models, and there are no published head-to-head trials comparing bremelanotide with flibanserin (the other FDA-approved HSDD drug), with testosterone, or with psychosexual therapy. What is directly studied: the 1.75 mg subcutaneous dose in premenopausal women with acquired, generalized HSDD. What is extrapolated: the mechanism of action in women, long-term efficacy beyond 52 weeks, and any benefit in postmenopausal women or women with situational HSDD.

As the RECONNECT authors note in the published trial report, "bremelanotide significantly improved sexual desire and reduced distress related to low sexual desire compared with placebo", while also acknowledging that effect sizes were small to moderate.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

Bremelanotide is contraindicated in pregnancy. This is not a theoretical caution. It is a hard contraindication based on animal reproductive toxicity data.

Animal Data and Pregnancy Risk

In animal studies, bremelanotide at doses comparable to human therapeutic exposure caused fetal developmental toxicity. The FDA label specifies that subcutaneous administration to pregnant rats and rabbits produced increases in fetal malformations and fetal losses at clinically relevant exposures. There are no adequate human pregnancy data. Given the indication (HSDD, a condition that does not require treatment to preserve maternal health), the risk-benefit calculation in pregnancy is straightforward: do not use it.

Palatin maintains a pregnancy registry through the FDA, and any inadvertent exposure should be reported.

Contraception Requirement

Because the drug is used on an as-needed basis by premenopausal women who may be sexually active, reliable contraception is required before starting bremelanotide. The label does not specify a contraception type, but clinicians generally recommend non-hormonal methods or hormonal methods with consistent use, noting that the relationship between hormonal contraception and baseline sexual desire is itself a clinical variable. Women who are trying to conceive should not use bremelanotide and should discontinue the drug before attempting pregnancy.

Lactation

There are no human lactation data. Based on the drug's molecular weight and pharmacokinetic profile, transfer into breast milk is possible. The FDA label advises against use during breastfeeding because of the absence of safety data and the availability of alternative approaches to managing HSDD postpartum. For postpartum women experiencing low sexual desire, addressing sleep deprivation, hormonal changes of lactation (including hypoestrogenism and elevated prolactin), and relationship factors is the recommended first approach before any pharmacologic intervention.

Life-Stage Breakdown: Who This Drug Was Studied In, and Who It Was Not

Reproductive Years (Premenopausal Women)

This is the approved and studied population. The RECONNECT trials required women to be premenopausal, aged 18 to 50, with at least 6 months of low desire causing personal distress, and with no current major depressive disorder or relationship conflict identified as the primary driver. If that description fits your situation, you are in the group where the clinical evidence exists.

Cycle phase at time of dosing was not systematically analyzed in RECONNECT, which is a gap. Anecdotally, clinicians who prescribe the drug have noted that women report variable response across the cycle, which is biologically plausible given that hypothalamic melanocortin tone is at least partially modulated by estradiol.

Trying to Conceive

Do not use bremelanotide. The contraindication in pregnancy and the requirement for contraception mean that the drug is incompatible with an active conception attempt.

Perimenopause and Menopause

Bremelanotide has not been approved for postmenopausal women. Phase 2 data in postmenopausal women existed before the RECONNECT program, but Palatin pursued only the premenopausal indication for Phase 3. The Menopause Society notes that HSDD is highly prevalent in the menopause transition, affecting roughly 30 to 40% of women, and that available pharmacologic options remain limited. Off-label use in postmenopausal women occurs in clinical practice, but the evidence base is thin, and women in this life stage should understand they are outside the studied population.

Postmenopausal women with HSDD who have inadequate responses to hormone therapy (systemic estrogen plus testosterone, if used off-label) and psychosexual counseling may be offered bremelanotide by clinicians familiar with the off-label use, but that should be a clearly informed, documented conversation.

Postpartum and Lactating Women

Not indicated. Low sexual desire in the postpartum period is extremely common, affecting up to 80% of women in the first year after delivery, and is driven by a complex mix of sleep deprivation, breastfeeding-associated hypoestrogenism, elevated prolactin suppressing desire, body image shifts, and relationship adjustment. None of these causes are addressed by bremelanotide, and the drug should not be used while breastfeeding.

Side Effects, Blood Pressure, and Why Cardiovascular History Matters

The most clinically significant adverse effects documented across the RECONNECT trials and Phase 2 studies are nausea (affecting roughly 40% of users in trials), flushing, and transient blood pressure elevation.

The Blood Pressure Signal

In the Phase 3 trials, bremelanotide caused a mean maximum increase of approximately 6 mmHg in systolic blood pressure and 3 mmHg in diastolic blood pressure, peaking at approximately 30 to 60 minutes post-dose and returning to baseline by 12 hours. This was the same signal that stalled the erectile dysfunction program in men, though the magnitude was smaller in women. Women with uncontrolled hypertension or cardiovascular disease were excluded from the trials, and the drug carries a contraindication in that group.

For a healthy premenopausal woman with normal blood pressure, the transient elevation is unlikely to be clinically consequential. For a woman with borderline hypertension or a history of cardiovascular events, bremelanotide is contraindicated.

Nausea Management

Nausea is the most common reason women discontinue the drug. In the RECONNECT trials, approximately 13% of women discontinued due to nausea. The manufacturer recommends taking the injection approximately 45 minutes before anticipated sexual activity and notes that nausea typically peaks within the first hour and resolves by 3 hours post-dose. Pre-treating with an antiemetic is used by some prescribers off-label but is not part of the label recommendation.

Where Bremelanotide Fits in the Current Treatment Field for HSDD

Bremelanotide is one of two FDA-approved treatments for HSDD in premenopausal women. The other is flibanserin (Addyi), a serotonin receptor partial agonist taken daily that was approved in 2015. The American College of Obstetricians and Gynecologists notes that both agents have modest effect sizes and that non-pharmacologic approaches, including sex therapy and couples counseling, should be considered first-line or concurrent treatment.

Off-label testosterone therapy, particularly transdermal testosterone at low doses, has a larger evidence base in postmenopausal women and is commonly used off-label in premenopausal women with HSDD. No head-to-head trial of bremelanotide versus testosterone in premenopausal women exists.

The practical difference between flibanserin and bremelanotide: flibanserin requires daily dosing and has a significant alcohol interaction contraindication; bremelanotide is taken as needed, which some women prefer. Neither drug requires a specific hormone level to be present or absent for efficacy.

Regulatory Timeline: Key Dates in Bremelanotide's Approval

• 1981: Hadley and Hruby begin synthesizing alpha-MSH analogues at University of Arizona.
• 1996: Self-administration case report of MT-II describes spontaneous erection; published in Annals of Pharmacotherapy.
• Early 2000s: Palatin Technologies begins IND work on PT-141; intranasal and subcutaneous formulations tested in men.
• 2004: Phase 2 intranasal data in men published showing pro-erectile and pro-desire effects with blood pressure signal.
• 2008: Phase 2 subcutaneous data in premenopausal women published in Journal of Sexual Medicine showing significant improvement in desire and arousal.
• 2016-2017: RECONNECT Phase 3 trials enroll and complete.
• 2019: RECONNECT results published in Obstetrics and Gynecology.
• June 21, 2019: FDA approves bremelanotide (Vyleesi) 1.75 mg subcutaneous injection for acquired, generalized HSDD in premenopausal women.
• 2022: AbbVie acquires rights for commercialization from Palatin Technologies.

Who This Drug Is Right For, and Who It Is Not

Right for you if:

• You are a premenopausal woman with a confirmed diagnosis of acquired, generalized HSDD (low desire causing personal distress, not explained by a relationship problem, medication, or another condition).
• Your desire was adequate at some point and has since decreased, ruling out lifelong low desire.
• You have normal blood pressure with no cardiovascular history.
• You are using reliable contraception and not trying to conceive.
• You prefer an as-needed medication over a daily pill.

Not right for you if:

• You are pregnant, breastfeeding, or trying to conceive.
• You have uncontrolled hypertension or a history of cardiovascular disease or stroke.
• Your low desire is situational (only with a specific partner, only during certain circumstances), as the RECONNECT trials enrolled women with generalized HSDD.
• Your primary concern is genital arousal disorder, orgasm difficulty, or pain, rather than desire.
• You are postmenopausal and want an FDA-approved option. The approval does not cover you, and prescribing in this population is off-label.